Molly Henderson - 07 Apr 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: CFO and CBO
Issuer ticker: PHAT
Reported as of: 07 Apr 2025
Net transaction value: -$16,740
SEC form: 4
Accepted by SEC: 08 Apr 2025, 17:01:33 UTC
Prior SEC filing: 03 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Molly Henderson

Key filing fact

Molly Henderson filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 08 Apr 2025.

Key facts

This page summarizes Molly Henderson's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Apr 2025, 17:01.

Change

Previous filing in this sequence was filed on 03 Mar 2025.
Current net transaction value: -$16,740.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHAT transaction

Common Stock

Sale

Transaction value: $16,740
Shares: -3,678
Change %: -3.9%
Price: $4.55
Shares after: 89,868
Date: 07 Apr 2025
Ownership: Direct
Footnotes: F1, F2

PHAT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,911
Date: 07 Apr 2025
Ownership: By 401(k)

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $4.55 to $4.57. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.